CR20230478A - Compuestos de tienopirrol. - Google Patents
Compuestos de tienopirrol.Info
- Publication number
- CR20230478A CR20230478A CR20230478A CR20230478A CR20230478A CR 20230478 A CR20230478 A CR 20230478A CR 20230478 A CR20230478 A CR 20230478A CR 20230478 A CR20230478 A CR 20230478A CR 20230478 A CR20230478 A CR 20230478A
- Authority
- CR
- Costa Rica
- Prior art keywords
- compounds
- present description
- lupus erythematosus
- pharmaceutical compositions
- thienopyrrole compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción se relaciona generalmente con ciertos compuestos, composiciones farmacéuticas que comprenden dichos compuestos y métodos para preparar y usar dichos compuestos y composiciones farmacéuticas. Los compuestos y composiciones proporcionados en la presente descripción pueden usarse para el tratamiento o prevención de una enfermedad autoinmunitaria y/o condición inflamatoria, que incluye el lupus eritematoso sistémico y lupus eritematoso cutáneo.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163176109P | 2021-04-16 | 2021-04-16 | |
| US202163216418P | 2021-06-29 | 2021-06-29 | |
| US202263305610P | 2022-02-01 | 2022-02-01 | |
| PCT/US2022/024984 WO2022221642A1 (en) | 2021-04-16 | 2022-04-15 | Thienopyrrole compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230478A true CR20230478A (es) | 2023-11-30 |
Family
ID=81580723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230478A CR20230478A (es) | 2021-04-16 | 2022-04-15 | Compuestos de tienopirrol. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11661431B2 (es) |
| EP (1) | EP4323369A1 (es) |
| JP (1) | JP2024513945A (es) |
| KR (1) | KR20230171469A (es) |
| AU (1) | AU2022257039A1 (es) |
| BR (1) | BR112023021107A2 (es) |
| CA (1) | CA3214808A1 (es) |
| CL (1) | CL2023002998A1 (es) |
| CO (1) | CO2023013397A2 (es) |
| CR (1) | CR20230478A (es) |
| DO (1) | DOP2023000219A (es) |
| IL (1) | IL307203A (es) |
| MX (1) | MX2023012110A (es) |
| PE (1) | PE20240919A1 (es) |
| WO (1) | WO2022221642A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI849499B (zh) * | 2021-09-10 | 2024-07-21 | 美商基利科學股份有限公司 | 噻吩并吡咯化合物 |
| WO2023247670A1 (en) * | 2022-06-24 | 2023-12-28 | F. Hoffmann-La Roche Ag | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
| WO2024108154A2 (en) * | 2022-11-18 | 2024-05-23 | The United States Government As Represented By The Department Of Veterans Affairs | Methods for treating rheumatoid arthritis using a syndecan-1 inhibitor or syntenin-1 inhibitor |
| WO2024182811A1 (en) * | 2023-03-02 | 2024-09-06 | University Of South Florida | Compositions and methods for treating uterine leiomyomas |
Family Cites Families (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| GB9718833D0 (en) | 1997-09-04 | 1997-11-12 | Merck Sharp & Dohme | Therapeutic agents |
| US6329412B1 (en) | 1997-11-04 | 2001-12-11 | Pfizer Inc | Bisamidine compounds as antiproliferative agents |
| US8691859B2 (en) | 2005-08-12 | 2014-04-08 | The United States Of America As Represented By The Secretary Of The Army | Broad spectrum antibacterial compounds |
| KR20080035700A (ko) | 2005-08-15 | 2008-04-23 | 아이알엠 엘엘씨 | Ｔｐｏ 모방체로서의 화합물 및 조성물 |
| EP1779848A1 (en) | 2005-10-28 | 2007-05-02 | Nikem Research S.R.L. | V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases |
| KR20090033881A (ko) * | 2006-07-14 | 2009-04-06 | 제네랩스 테크놀로지스, 인코포레이티드 | 항바이러스제 |
| CN101583598B (zh) | 2007-01-15 | 2012-09-12 | 参天制药株式会社 | 具有IκB激酶β抑制活性的新型吲哚衍生物 |
| KR101737753B1 (ko) | 2007-03-12 | 2017-05-18 | 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 | 페닐 아미노 피리미딘 화합물 및 이의 용도 |
| WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
| EP2350032B1 (en) | 2008-09-26 | 2016-05-25 | Eisai R&D Management Co., Ltd. | Benzoxazole compounds and methods of use |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| US9359361B2 (en) | 2011-06-01 | 2016-06-07 | Janus Biotherapeutics, Inc. | Immune system modulators |
| CA2837207A1 (en) | 2011-06-01 | 2012-12-06 | Janus Biotherapeutics, Inc. | Novel immune system modulators |
| WO2013052263A2 (en) | 2011-09-16 | 2013-04-11 | Microbiotix, Inc. | Antifungal compounds |
| IN2014KN00948A (es) | 2011-10-04 | 2015-08-21 | Janus Biotherapeutics Inc | |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| KR101452579B1 (ko) | 2012-08-17 | 2014-10-21 | 주식회사 두산 | 신규 화합물 및 이를 포함하는 유기 전계 발광 소자 |
| KR102365952B1 (ko) | 2013-10-14 | 2022-02-22 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 선택적으로 치환된 퀴놀린 화합물 |
| EP3057964B1 (en) | 2013-10-14 | 2019-12-04 | Eisai R&D Management Co., Ltd. | Selectively substituted quinoline compounds |
| EP3398948A3 (en) | 2014-08-22 | 2018-12-05 | Janus Biotherapeutics, Inc. | 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
| SG11201706542TA (en) | 2015-03-30 | 2017-10-30 | Mission Therapeutics Ltd | 1-cyano-pyrrolidine compounds as usp30 inhibitors |
| CA3003930A1 (en) | 2015-11-04 | 2017-05-11 | Simon Fraser University | Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor |
| SI3889145T1 (sl) | 2015-12-17 | 2024-05-31 | Merck Patent Gmbh | 8-ciano-5-piperidino-kinolini kot antagonisti tlr7/8 in njihove uporabe za zdravljenje imunskih motenj |
| CN109195972B (zh) | 2016-04-15 | 2022-10-28 | 癌症研究科技有限公司 | 作为ret激酶抑制剂的杂环化合物 |
| JP6964072B2 (ja) | 2016-04-26 | 2021-11-10 | 大日本住友製薬株式会社 | 置換プリン誘導体 |
| US10071079B2 (en) | 2016-06-29 | 2018-09-11 | Bristol-Myers Squibb Company | [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds |
| AU2017307208B2 (en) | 2016-07-30 | 2021-01-21 | Bristol-Myers Squibb Company | Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors |
| ES2944573T3 (es) | 2016-08-08 | 2023-06-22 | Merck Patent Gmbh | Antagonistas de TLR7/8 y usos de los mismos |
| BR112019004597A2 (pt) | 2016-09-09 | 2019-06-11 | Novartis Ag | compostos e composições como inibidores de receptores endossomais do tipo toll |
| CN109923108B (zh) | 2016-09-09 | 2022-04-29 | 百时美施贵宝公司 | 吡啶基取代的吲哚化合物 |
| AU2018302026B2 (en) | 2017-07-18 | 2022-04-07 | Merck Patent Gmbh | TLR7/8 antagonists and uses thereof |
| KR102651947B1 (ko) | 2017-08-04 | 2024-03-26 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물 |
| US11130756B2 (en) | 2017-08-04 | 2021-09-28 | Bristol-Myers Squibb Company | [1,2,4]Triazolo[4,3-A]pyridinyl substituted indole compounds |
| JP2021035910A (ja) | 2017-11-01 | 2021-03-04 | 大日本住友製薬株式会社 | 置換プリン化合物 |
| AU2018364807B2 (en) | 2017-11-08 | 2022-05-19 | Council Of Scientific & Industrial Research | Purine based compounds as toll-like receptor 9 antagonist |
| ES2945435T3 (es) | 2017-11-14 | 2023-07-03 | Bristol Myers Squibb Co | Compuestos de indol sustituidos |
| EA202091477A1 (ru) | 2017-12-15 | 2020-10-28 | Бристол-Маерс Сквибб Компани | Замещенные соединения простых индольных эфиров |
| ES2960411T3 (es) | 2017-12-18 | 2024-03-04 | Bristol Myers Squibb Co | Compuestos de 4-azaindol |
| JP7313354B2 (ja) | 2017-12-19 | 2023-07-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物 |
| EA202091508A1 (ru) | 2017-12-19 | 2020-09-14 | Бристол-Маерс Сквибб Компани | 6-азаиндольные соединения |
| RU2020123151A (ru) | 2017-12-19 | 2022-01-20 | Мерк Патент Гмбх | Антагонисты tlr7/8 и их применение |
| SG11202005696YA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Substituted indole compounds useful as tlr inhibitors |
| MX2020005513A (es) | 2017-12-20 | 2020-09-03 | Bristol Myers Squibb Co | Compuestos de amino indol utiles como inhibidores de receptores tipo toll (tlr). |
| WO2019126083A1 (en) | 2017-12-20 | 2019-06-27 | Bristol-Myers Squibb Company | Diazaindole compounds |
| JP7291707B2 (ja) | 2017-12-20 | 2023-06-15 | ブリストル－マイヤーズ スクイブ カンパニー | アリールおよびヘテロアリール置換されたインドール化合物 |
| CN111432818A (zh) | 2017-12-22 | 2020-07-17 | 诺华股份有限公司 | 用于治疗神经精神性系统性红斑狼疮的吡唑并哌啶衍生物和吡唑并嘧啶衍生物 |
| AR117573A1 (es) | 2018-05-18 | 2021-08-18 | Novartis Ag | Formas cristalinas de un inhibidor tlr7 / tlr8 |
| CN112513024A (zh) | 2018-07-31 | 2021-03-16 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| JP2022505827A (ja) | 2018-10-24 | 2022-01-14 | ブリストル－マイヤーズ スクイブ カンパニー | 置換インドール二量体の化合物 |
| US20210403468A1 (en) | 2018-10-24 | 2021-12-30 | Bristol-Myers Squibb Company | Substituted indole and indazole compounds |
| KR20220005554A (ko) | 2019-05-07 | 2022-01-13 | 브리스톨-마이어스 스큅 컴퍼니 | 전구약물 화합물 |
| CN114126713B (zh) | 2019-05-09 | 2023-12-08 | 百时美施贵宝公司 | 经取代的苯并咪唑酮化合物 |
| JP2022534038A (ja) | 2019-05-23 | 2022-07-27 | ザ ユニバーシティー オブ モンタナ | Ｔｌｒ受容体リガンドをベースとするワクチンアジュバント |
| US20240124489A1 (en) * | 2019-10-01 | 2024-04-18 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
| US20240076280A1 (en) | 2019-10-04 | 2024-03-07 | Bristol-Myers Squibb Company | Substituted carbazole compounds |
| US20230117470A1 (en) | 2019-11-01 | 2023-04-20 | Bristol-Myers Squibb Company | Substituted pyrazole compounds as toll receptor inhibitors |
| CA3177685A1 (en) | 2020-05-14 | 2021-11-18 | Julie A. Demartino | Tlr7/8 antagonists for the treatment of coronavirus infections |
| US20230310408A1 (en) | 2020-06-11 | 2023-10-05 | Bristol-Myers Squibb Company | Tlr7 inhibitor in combination with prednisolone or hydroxychloroquine for treating cutaneous lupus erythematosus |
| EP4168049A1 (en) | 2020-06-22 | 2023-04-26 | Bristol-Myers Squibb Company | Treating rheumatoid arthritis |
| TW202214632A (zh) | 2020-07-27 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚稠環類衍生物、其製備方法及其在醫藥上的應用 |
| CN114075219B (zh) | 2020-08-14 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 喹啉稠环类衍生物、其制备方法及其在医药上的应用 |
| CN114075212B (zh) | 2020-08-14 | 2023-05-12 | 江苏恒瑞医药股份有限公司 | 稠合三环类衍生物、其制备方法及其在医药上的应用 |
| PE20231318A1 (es) | 2020-08-19 | 2023-08-24 | Bristol Myers Squibb Co | Compuestos heteroarilicos sustituidos utiles como inhibidores de tlr9 |
| JP2023550793A (ja) | 2020-11-26 | 2023-12-05 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 縮合三環式化合物、その調製方法及びその医薬的応用 |
| TW202241419A (zh) | 2020-12-22 | 2022-11-01 | 美商基利科學股份有限公司 | ６－取代之吲哚化合物 |
| EP4267559A1 (en) | 2020-12-22 | 2023-11-01 | Gilead Sciences, Inc. | Substituted indole compounds |
-
2022
- 2022-04-15 CR CR20230478A patent/CR20230478A/es unknown
- 2022-04-15 AU AU2022257039A patent/AU2022257039A1/en active Pending
- 2022-04-15 JP JP2023562311A patent/JP2024513945A/ja active Pending
- 2022-04-15 IL IL307203A patent/IL307203A/en unknown
- 2022-04-15 MX MX2023012110A patent/MX2023012110A/es unknown
- 2022-04-15 US US17/721,636 patent/US11661431B2/en active Active
- 2022-04-15 PE PE2023002819A patent/PE20240919A1/es unknown
- 2022-04-15 KR KR1020237039381A patent/KR20230171469A/ko unknown
- 2022-04-15 CA CA3214808A patent/CA3214808A1/en active Pending
- 2022-04-15 EP EP22721581.1A patent/EP4323369A1/en active Pending
- 2022-04-15 BR BR112023021107A patent/BR112023021107A2/pt unknown
- 2022-04-15 WO PCT/US2022/024984 patent/WO2022221642A1/en active Application Filing
-
2023
- 2023-03-08 US US18/180,438 patent/US20230365594A1/en active Pending
- 2023-10-06 CL CL2023002998A patent/CL2023002998A1/es unknown
- 2023-10-09 DO DO2023000219A patent/DOP2023000219A/es unknown
- 2023-10-09 CO CONC2023/0013397A patent/CO2023013397A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20240919A1 (es) | 2024-04-30 |
| TW202302598A (zh) | 2023-01-16 |
| US11661431B2 (en) | 2023-05-30 |
| CO2023013397A2 (es) | 2023-10-30 |
| CL2023002998A1 (es) | 2024-04-26 |
| JP2024513945A (ja) | 2024-03-27 |
| BR112023021107A2 (pt) | 2023-12-12 |
| MX2023012110A (es) | 2023-10-24 |
| IL307203A (en) | 2023-11-01 |
| KR20230171469A (ko) | 2023-12-20 |
| EP4323369A1 (en) | 2024-02-21 |
| CA3214808A1 (en) | 2022-10-20 |
| WO2022221642A1 (en) | 2022-10-20 |
| DOP2023000219A (es) | 2023-11-15 |
| US20230365594A1 (en) | 2023-11-16 |
| US20220389034A1 (en) | 2022-12-08 |
| AU2022257039A1 (en) | 2023-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023013397A2 (es) | Compuestos de tienopirrol | |
| CL2020002841A1 (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| CO2020014009A2 (es) | Inhibidores de mcl-1 | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| CO2020015153A2 (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| DOP2015000234A (es) | COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO. | |
| AR106768A1 (es) | Composiciones que comprenden cepas bacterianas | |
| UY37098A (es) | Moduladores de ror-gamma | |
| SV2017005471A (es) | Derivados de quinazolina utilizados para tratar el vih | |
| SV2017005461A (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
| CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
| CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
| CL2022002695A1 (es) | Inhibidores de rip1k | |
| MX2021004999A (es) | Administracion de butirato, beta-hidroxibutirato, cannabidiol y compuestos relacionaods en seres humanos. | |
| CL2020000220A1 (es) | Composiciones que comprenden aminoácidos para su uso en el tratamiento de enfermedades relacionadas con la disfunción mitocondrial. | |
| PE20200338A1 (es) | Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil | |
| AR103350A1 (es) | Composiciones del inhibidor de la nitrificación y métodos de preparación de las mismas | |
| BR112017010933A2 (pt) | composição farmacêutica | |
| AR102780A1 (es) | Composiciones farmacéuticas, su preparación y sus usos | |
| CL2022003812A1 (es) | Inhibidores de rip1k | |
| CL2009000599A1 (es) | Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras. | |
| CL2016002400A1 (es) | Formulación para higiene personal | |
| AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| AR103607A1 (es) | Composición farmacéutica para la aplicación tópica en el conducto auditivo | |
| DOP2018000211A (es) | Composiciones y métodos para estabilizar alfavirus con formulaciones mejoradas |